Loading market movers...

Odronextamab

Phase 3

Regeneron Pharmaceuticals, Inc. (REGN)

00%

Phase 3

Development Phase

1

Upcoming Catalysts

0

Historical Events

1

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

Jan '27

REGNPhase 2$75.2B

Odronextamab Phase 2 Est. Readout

Odronextamab• Diffuse Large B-cell Lymphoma (DLBCL)35

Jan 2027~Estimated

00%

Competitive Landscape

1 competitor in Diffuse Large B-cell Lymphoma (DLBCL)

EPZMTazemetostat

View Full Landscape

Drug Information

Target Indication

Diffuse Large B-cell Lymphoma (DLBCL)

Clinical Trial

Last updated: 1/2/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Regulatory Approvals

EMA8/22/2024

Ordspono

Ordspono as monotherapy is indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma (r/r FL) after two or more lines of systemic therapy. Ordspono as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL) after two or more lines of systemic therapy.

OrphanConditional

Drug Science

Mechanism of action & safety profile

Developer

REGN

Regeneron Pharmaceuticals, Inc.

Pharmaceutical Preparations•North America•NASDAQ

Related Pipeline

AlirocumabPhase 3

Homozygous Familial Hypercholesterolemia

Hypercholesterolemia

Non-Small Cell Lung Cancer

Intravitreal Aflibercept Injection (IAI)Phase 3

Neovascular Age-Related Macular Degeneration

REGN5715Phase 3

Allergic Conjunctivitis

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts